This company listing is no longer active
Oncoinvent (ONCOI) Stock Overview
A clinical stage company, develops radiopharmaceutical therapies against cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ONCOI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Oncoinvent ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 1.33 |
| 52 Week High | NOK 4.00 |
| 52 Week Low | NOK 1.15 |
| Beta | 0 |
| 1 Month Change | 2.15% |
| 3 Month Change | -11.10% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONCOI | NO Pharmaceuticals | NO Market | |
|---|---|---|---|
| 7D | -4.9% | -2.7% | -0.8% |
| 1Y | n/a | -11.1% | 6.2% |
Return vs Industry: Insufficient data to determine how ONCOI performed against the Norwegian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ONCOI performed against the Norwegian Market.
Price Volatility
| ONCOI volatility | |
|---|---|
| ONCOI Average Weekly Movement | 11.7% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in NO Market | 10.8% |
| 10% least volatile stocks in NO Market | 2.5% |
Stable Share Price: ONCOI's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: ONCOI's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 36 | Oystein Soug | www.oncoinvent.com |
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, alpha-radiation therapy candidate designed for the direct targeting of cancers that have spread to body cavities, like the peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company was incorporated in 2010 and is based in Oslo, Norway.
Oncoinvent ASA Fundamentals Summary
| ONCOI fundamental statistics | |
|---|---|
| Market cap | NOK 130.00m |
| Earnings (TTM) | -NOK 106.73m |
| Revenue (TTM) | NOK 20.00m |
Is ONCOI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCOI income statement (TTM) | |
|---|---|
| Revenue | NOK 20.00m |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 20.00m |
| Other Expenses | NOK 126.72m |
| Earnings | -NOK 106.73m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 04, 2025
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 100.00% |
| Net Profit Margin | -533.74% |
| Debt/Equity Ratio | 0% |
How did ONCOI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 15:39 |
| End of Day Share Price | 2025/10/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncoinvent ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geir Holom | DNB Carnegie |